These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12823686)

  • 21. The ALLHAT report: a case of information and misinformation.
    Weber MA
    J Clin Hypertens (Greenwich); 2003; 5(1):9-13. PubMed ID: 12556647
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
    Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK; Barzilay J; Cushman WC; Davis BR; Iiamathi E; Kostis JB; Leenen FH; Louis GT; Margolis KL; Mathis DE; Moloo J; Nwachuku C; Panebianco D; Parish DC; Pressel S; Simmons DL; Thadani U;
    Arch Intern Med; 2005 Jun; 165(12):1401-9. PubMed ID: 15983290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diuretics: older, cheaper, better.
    Johns Hopkins Med Lett Health After 50; 2003 Apr; 15(2):1-2. PubMed ID: 12712964
    [No Abstract]   [Full Text] [Related]  

  • 25. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Ernst ME; Davis BR; Soliman EZ; Prineas RJ; Okin PM; Ghosh A; Cushman WC; Einhorn PT; Oparil S; Grimm RH;
    J Am Soc Hypertens; 2016 Dec; 10(12):930-938.e9. PubMed ID: 27938852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALLHAT: still providing correct answers after 7 years.
    Einhorn PT; Davis BR; Wright JT; Rahman M; Whelton PK; Pressel SL;
    Curr Opin Cardiol; 2010 Jul; 25(4):355-65. PubMed ID: 20520537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial therapy of hypertension.
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1140-2. PubMed ID: 15863559
    [No Abstract]   [Full Text] [Related]  

  • 29. Results of the ALLHAT trial: is the debate about initial antihypertensive drug therapy over?
    Moser M
    J Clin Hypertens (Greenwich); 2003; 5(1):5-8. PubMed ID: 12556646
    [No Abstract]   [Full Text] [Related]  

  • 30. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Düsing R
    Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
    [No Abstract]   [Full Text] [Related]  

  • 31. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
    Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
    Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
    Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
    Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
    J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
    J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
    Wright JT; Probstfield JL; Cushman WC; Pressel SL; Cutler JA; Davis BR; Einhorn PT; Rahman M; Whelton PK; Ford CE; Haywood LJ; Margolis KL; Oparil S; Black HR; Alderman MH;
    Arch Intern Med; 2009 May; 169(9):832-42. PubMed ID: 19433694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALLHAT finds diuretics best for initial hypertension therapy.
    Traynor K
    Am J Health Syst Pharm; 2003 Feb; 60(3):222, 224. PubMed ID: 12613228
    [No Abstract]   [Full Text] [Related]  

  • 39. [ALLHAT--the most comprehensive antihypertensive treatment trial in the world. The significance of thiazide diuretics for patients older than 55 years is confirmed].
    Nilsson P
    Lakartidningen; 2003 Feb; 100(6):400-4, 407. PubMed ID: 12607431
    [No Abstract]   [Full Text] [Related]  

  • 40. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
    J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.